HUTCHMED (China) Limited American Depositary Shares (HCM)

Dr. Weiguo Su is taking a medical leave of absence as CEO, with Johnny Cheng appointed as Acting CEO. The board expressed full support for Dr. Su and confidence in Mr. Cheng's leadership during this interim period.

Hutchmed divests 45% equity in SHPL for $608 million, allowing it to focus on its core cancer drug development business. The company also received priority review for a lung cancer drug combination from China's NMPA.

HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After years of ‘lackluster’ efforts, regulators and companies are finally aligned in their goal to make clinical trials more representative of U.S. population.

The risks of investing in Chinese stocks are growing.